US EditionWorld-first blood cancer therapy to be given on NHS
- NHS England is fast-tracking the use of belantamab mafodotin, a targeted 'Trojan horse' therapy, for multiple myeloma patients from today in England.
- This follows NICE's approval, which confirmed the drug's cost-effectiveness after clinical trial results showed it delays disease progression significantly.
- Trials last year showed that Blenrep combined with bortezomib and dexamethasone extended progression-free survival to around three years versus just over a year with current therapies.
- Approximately 1,500 patients annually whose multiple myeloma has progressed after first-line treatment will now have access to this therapy, which patients and officials describe as life-changing.
- This makes the NHS the pioneering health service globally to provide this cutting-edge treatment, which could enhance both survival rates and quality of life for many patients with this incurable cancer.
Insights by Ground AI
Does this summary seem wrong?
27 Articles
27 Articles
All
Left
4
Center
9
Right
4
Cancer patient hails 'life-changing' new treatment with NHS to become first to offer therapy worldwide
The NHS in England has become the first healthcare system worldwide to provide a groundbreaking cancer treatment that can significantly extend the lives of myeloma patients. The therapy, called belantamab mafodotin, represents a major advance in treating this incurable blood cancer.Clinical trials have demonstrated that this innovative treatment can halt the progression of myeloma for three years, a dramatic improvement over existing therapies t…
·London, United Kingdom
Read Full Article
Coverage Details
Total News Sources27
Leaning Left4Leaning Right4Center9Last UpdatedBias Distribution53% Center
Bias Distribution
- 53% of the sources are Center
53% Center
L 24%
C 53%
R 24%
Factuality
To view factuality data please Upgrade to Premium
